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Abstract: 1 
Objectives: To determine the accuracy of pharmaceutical companies’ predictions of 2 
drug licensing timeframes for their products in late stage clinical development. 3 
Methods: We compared predicted licensing dates provided to the National Institute 4 
for Health Research Horizon Scanning Research and Intelligence Centre (NIHR 5 
HSRIC) by pharmaceutical companies against actual market authorisation 6 
application (MAA) and authorisation (MA) dates published by the European 7 
Medicines Agency for drugs granted authorisation between 2009 and 2013.  8 
Key findings: 123 drugs met our inclusion criteria.  78% were new drugs and 16% 9 
had orphan designation. Less than half (44%) and less than a quarter (24%) of MAA 10 
and MA predictions respectively were considered accurate (same month or one 11 
month either side of the actual date). Pharmaceutical companies were significantly 12 
more accurate in predicting MAA dates than MA dates (p<0.001). For accurate 13 
predictions, the mean duration between the prediction being made and the actual 14 
MAA and MA dates were 17.5 and 18.7 months, respectively. Out of the total 108 15 
MA predictions, almost two-thirds (65.4%, 16/26) of short-term predictions (made in 16 
the two years prior to the actual MA) were accurate. For predicted dates that were 17 
earlier than the actual MA date, there was a positive relationship between accuracy 18 
and the time between the prediction and authorisation. 19 
Conclusions: Even in predicting near events from well-informed sources, accuracy 20 
is imperfect. There appears to be an optimum time for the provision of accurate 21 
information on predicted MAA and MA dates for drugs. This information is crucial for 22 
effective early awareness and alert activities.  23 
Key words: Pharmaceutical, licensing, prediction, horizon scanning, early 24 
awareness and alert systems 25 
 26 
 27 
 28 
 29 
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Introduction 1 
New drugs and new indications for existing licensed drugs have the potential to bring 2 
about important change in medical practice leading to benefits for patients, clinicians 3 
and health services. They can improve the quality of patients’ lives through improved 4 
management of disease, enable patients to remain in their homes rather than in 5 
hospitals, simplify treatment schedules, and allow clinicians to treat patients more 6 
effectively and efficiently.[1] They can, of course, also confer net harm if they displace 7 
more cost-effective treatments. Before a drug can be marketed for a specific 8 
indication, it undergoes a process of licensing by the applicable medicines regulator, 9 
which then issues Marketing Authorisation (MA). The regulation of medicines 10 
ensures its safety and the protection of public health. In the UK, two regulators 11 
perform this function, the European Medicines Agency (EMA), which aims to 12 
streamline the licensing process and ensure a homogeneous regulatory policy 13 
throughout the European Union (EU), and the UK Medicines and Healthcare 14 
Products Regulatory Agency (MHRA).  15 
 16 
Early identification of imminent technologies enables decision makers to plan further 17 
evaluation, plan future investment, decide on the allocation of resources, identify 18 
requirements for implementation such as staff training and the development of 19 
facilities, and make changes to treatment and management pathways.[2] This, in turn, 20 
helps health systems incorporate such innovation in a sustainable way and facilitates 21 
appropriate adoption.[3-7] Timely evaluation and planning requires accurate 22 
information about probable launch dates, and a lack of accurate intelligence can 23 
hinder informed decision making with undesirable health and financial 24 
consequences.[8]  Most pharmaceutical companies begin speculation about the 25 
eventual date of licensing during phase II clinical development.[9] These discussions 26 
continue through the rest of the development process until the application for 27 
regulatory approval.  28 
 29 
Many countries have established early awareness and alert (EAA) systems (also 30 
known as horizon scanning or early warning systems), to provide decision makers 31 
with information on new health technologies prior to their introduction and adoption 32 
into health systems.[7,10] The National Institute for Health Research Horizon Scanning 33 
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Research and Intelligence Centre (NIHR HSRIC) [11] in England is an EAA system 1 
that provides advance notice on new and emerging health technologies and 2 
interventions, including drugs that are likely to have a significant impact on the 3 
English National Health Service (NHS) and/or patients within the next two to three 4 
years.[12] The system informs the topic selection and timing of health technology 5 
assessments (appraisals) undertaken by the National Institute for Health and Care 6 
Excellence (NICE). Key features of the NIHR HSRIC methods include extensive and 7 
proactive contact with pharmaceutical companies to identify products in development 8 
and obtain company predictions for future dates of marketing authorisation 9 
application (MAA or ‘filing’) and marketing authorisation (MA or ‘licence’) with the 10 
European Medicines Agency. Scanning for new medicines also includes scrutiny of 11 
relevant commercial and general media, scientific publications, commercial R&D 12 
databases, and access to the UK PharmaScan database of pharmaceuticals in 13 
development.[13] The NIHR HSRIC aims to produce information on new drugs and 14 
new indications for existing licensed drugs around twenty months and around fifteen 15 
months prior to launch, respectively.[14]  16 
 17 
Prediction, however, is not always accurate, and depends on the availability and 18 
quality of data. It is generally assumed that as a technology nears licensing, any 19 
predictions made about the timing of regulatory approval will be increasingly 20 
accurate.[15] Predictions from pharmaceutical companies on the anticipated timing of 21 
MAA and MA are of crucial importance to the work of the NIHR HSRIC. We aimed to 22 
determine how accurate such predictions have been, and if they varied according to 23 
the whether this was the first or subsequent indication for the drug, by orphan 24 
designation, as well as the time from making the prediction to subsequent licensing.  25 
 26 
Methods 27 
Design 28 
A cross-sectional study comparing predicted MAA and MA dates obtained from 29 
NIHR HSRIC contacts with pharmaceutical companies against actual MAA and MA 30 
dates for both new drugs and new indications for existing licensed drugs awarded 31 
MA between 2009 and 2013 (inclusive).   32 
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Data sources 1 
Information on drugs licensed between 2009 and 2013 (inclusive, and including 2 
those subsequently withdrawn), their indication, orphan designation, and dates of 3 
MA and MAA were obtained from the EMA website.[16]  4 
Data on individual predicted MAA and/or MA dates were obtained from the NIHR 5 
HSRIC’s confidential information system, which is populated with data obtained 6 
directly from commercial pharmaceutical companies. Data on whether the MA 7 
represented a new drug or a new indication for an existing licensed drug were 8 
obtained from the EMA website [16] and relevant editions of the British National 9 
Formulary (BNF).[17] 10 
Whilst all new drugs (new chemical entities and new biologic products) and new 11 
indications for existing licensed drugs receiving MA between 2009 and 2013 were 12 
eligible for inclusion in this study, only those with a company prediction for 13 
anticipated future MAA or MA dates available on the NIHR HSRIC information 14 
system were included in the analysis. Generic drugs, biosimilars, and blood products 15 
were excluded, as were vaccines and diagnostic agents, which have a different 16 
assessment and market access pathway in the United Kingdom. 17 
Data handling and analysis 18 
Differences in the duration between the predicted and actual MAA and MA dates 19 
were calculated to the nearest month. A prediction was considered accurate when 20 
the actual MAA or MA date fell in the same month as the prediction or in the month 21 
before or after the prediction.  22 
Statistical analysis was carried out using SPSS version 21 for Windows. Descriptive 23 
analyses were presented as means and standard deviations (SD) for normally 24 
distributed continuous variables, medians for skewed continuous data, and 25 
percentages for dichotomous variables. Significant differences were determined 26 
using ANOVA for continuous normally distributed data and X2 for dichotomous 27 
variables.  28 
 29 
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Results 1 
Data availability 2 
194 new drugs and new indications for existing licensed drugs were awarded MA by 3 
the EMA in the five-year study period between 2009 and 2013 (inclusive), of which 4 
123 (63.4%) had a company prediction of the likely MAA and/or MA date recorded in 5 
the NIHR HSRIC information system. Two thirds of these 123 drugs (65%) had both 6 
predicted MAA and MA dates available on the NIHR HSRIC database. More than 7 
three quarters of the drugs included in the analysis were new drugs (78.3%) rather 8 
than new indications for existing licensed drugs, and the majority did not have an 9 
orphan designation (84.0%). 10 
Accuracy of company predictions for MAA and MA dates 11 
Less than half (43.8%) and less than a quarter (24.1%) of MAA and MA predictions, 12 
respectively, were regarded as accurate. Out of the 80 drugs where predictions were 13 
available for both MA and MAA, only 9 (11.3%) drugs had accurate predictions for 14 
both MAA and MA (Table 1). The majority of errors were optimistic ones; with 28.8% 15 
of those predictions were expected to happen before the actual MA/MAA dates. The 16 
differences between the in the accuracy of predictions were statistically significant 17 
(McNemar-Bowker test =14.4, df=3, p=0.002). Company predictions for MAA dates 18 
ranged from seventy two months before the actual MAA date to twenty eight months 19 
after the actual MAA date. Company predictions for MA dates ranged from seventy 20 
five months before the actual MA date to fifteen months after the actual MA date.  21 
There was no difference in the percentage accuracy of MAA predictions between 22 
new drugs (44.3%) and new indications (45.5%). However, for MA, only 24.0% of 23 
predictions for new drugs were accurate compared to 30.8% for new indications, but 24 
this difference was not statistically significant. For drugs with predictions earlier than 25 
the actual dates, the mean number of months difference from the actual dates was 26 
less for new drugs (8.6 and 10.4 for MAA and MA respectively) than for new 27 
indications (14.6 and 7.3 months for MAA and MA respectively). For drugs with 28 
predictions later than the actual dates, the mean difference between actual and 29 
predicted dates was greater for new drugs (6.4 months for MAA and 4.8 for MA) than 30 
for new indications (3.0 months for MAA and 3.0 for MA). 31 
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Orphan designation made little difference to the percentage of accurate predictions 1 
(MAA, 50% and 43.2% and MA, 23.8% and 25%, for those with and without orphan 2 
designations, respectively), though an increase in the spread of data was observed 3 
in the accuracy of prediction for drugs without orphan designations. However, for 4 
drugs with predictions earlier than the actual dates, the mean difference between 5 
actual and predicted dates was less for drugs with an orphan designation (4.3 for 6 
MAA and 8.8 for MA) than those without an orphan designation (10.7 for MAA and 7 
10.3 for MA), but these differences were not statistically significant. However, for 8 
drugs with predictions later than the actual dates, this pattern was observed only for 9 
MAA (mean difference between actual and predicted dates for MAA, 4.3 for orphan 10 
and 10.7 for non-orphan drugs; mean difference between actual and predicted dates 11 
for MA, 7.3 for orphan and 4.2 for non-orphan drugs). 12 
 13 
Length of time between the prediction being received, actual MAA/MA date, and 14 
prediction accuracy  15 
More than half of company predictions for MA dates available on the NIHR HSRIC 16 
database (58.3%) were received within two years of the actual MA date (Table 2), 17 
and almost two thirds of accurate predictions (65.4%, 17 of 26) were found in this 18 
group. For predictions received more than 24 months prior to final MA, only 20% (9 19 
of 45) were accurate and the vast majority were optimistic (67%, 30 of 45). 20 
 21 
Cases where the company prediction was accurate for MAA had a statistically 22 
significantly shorter median length of duration between the date when predictions 23 
was received and the actual MAA date (Table 3, median 17.0 months, p< 0.0001). 24 
For the nine drugs where the predictions were accurate for both MAA and MA, the 25 
mean duration between the predictions was received and the actual MA date was 26 
15.8 months (SD 6.04, median 17, minimum 4 and maximum 26).   27 
 28 
For company predictions that were earlier than the actual MA date, there was a 29 
positive relationship between the length of time between making the prediction and 30 
the actual MA date, and the accuracy of prediction (y = 0.54x - 4.17, r = 0.70, R² = 31 
0.49, p=0.0001, Figure 1a). Visual inspection of the scatter plot suggested that the 32 
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three drugs with predictions received more than five years before actual MA date 1 
may be outliers. After their exclusion, there still remained a positive, but much 2 
weaker relationship between the length of time between receiving the company 3 
prediction and the actual licensing date, and the accuracy of prediction (y = 0.13x 4 
4.58, r=0.26, p=0.05). In contrast, no statistically significant relationship between 5 
prediction accuracy and the length of time between the prediction being received and 6 
actual MA date was seen for company predictions that were subsequently found to 7 
be later than the actual MA date (Figure 1b). 8 
 9 
Discussion 10 
Major findings of this study 11 
Our analysis showed that most company predictions of licensing dates were 12 
inaccurate, with less than half of pharmaceutical company predictions for MAA timing 13 
and less than a quarter of their predictions for MA timing falling within our definition 14 
of accurate (the same month or the month either side of the actual date). More than 15 
half of company predictions for MA were optimistic, being earlier than the actual 16 
date. Our findings regarding the accuracy of pharmaceutical company predictions 17 
agree with the general comments of other authors, who suggest that one cannot 18 
expect fully accurate predictions and that by their very nature some predictions will 19 
inevitably be wrong.[18-20] Accordingly, there are inherent limits to the accuracy of 20 
health care horizon scanning programmes and the future will always be uncertain.  21 
 22 
Pharmaceutical companies were more accurate in predicting the dates for MAA than 23 
for MA, which may be explained by the date of filing being at least partly under the 24 
company’s control, whilst the final MA date is primarily determined by the regulator. 25 
The maximum time taken for the EMA to conduct its review is limited by legislation, 26 
so that variations in the time taken for drugs to be awarded authorisation depends on 27 
whether more information is requested from the company to meet regulatory 28 
requirements. In this study neither orphan designation nor drug development status 29 
(in terms of being a new drug or a new indication for an existing licensed drug) made 30 
a significant difference to the accuracy of company predictions. 31 
 32 
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Implications for EAA systems 1 
Estimation of the potential timing of approval for new and emerging drugs is crucially 2 
important for early decision making and appropriate planning. A major objective of an 3 
effective EAA system is to provide sufficient notice to policy makers before a new 4 
drug or technology diffuses into a health care system, and monitoring of drug 5 
licensing is critical with accuracy a fundamental criterion.[21, 22] Acknowledging the 6 
challenge, the NIHR HSRIC performs extensive and proactive contact with 7 
pharmaceutical companies to identify products in company development pipelines 8 
and obtain predictions for licensing dates.[12] 9 
 10 
Making predictions is a complex process, and their accuracy and certainty is always 11 
open to question.[6, 23] Perhaps unsurprisingly, predictions received nearer to the time 12 
were more likely to be accurate. This finding needs to be considered when designing 13 
effective EAA systems as increasing uncertainty must be recognised when 14 
predictions are to be received a long time before the actual event.  Our results 15 
suggest that providing information on emerging drugs more than 2 years from 16 
estimated MAA or MA dates is likely to result in less accurate predictions. 17 
 18 
Strengths and limitations  19 
This is the first study to look comprehensively at the accuracy of pharmaceutical 20 
companies’ predictions for the expected dates of their drugs’ marketing authorisation 21 
application and subsequent authorisation. Although we have been able to use the 22 
NIHR HSRIC extensive internal information system to provide company predictions, 23 
we were limited by data availability: not all the drugs licensed in the period of our 24 
study had company predictions available on the NIHR HSRIC database, and not all 25 
drugs for which there were predictions had predicted dates available for both MAA 26 
and MA. In addition, the availability of the data depends on the NIHR HSRIC data 27 
collecting efforts. For this study, the last available information from the company prior 28 
to the NIHR HSRIC producing an output was taken as the final predicted MAA or MA 29 
date. 30 
 31 
 32 
 33 
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Conclusion 1 
This study suggests that the current timescales used by the NIHR HSRIC to inform 2 
the NICE topic selection process are valid and provide a reasonable balance 3 
between earliness and accuracy. But making predictions for drug licensing 4 
timeframes even when using well informed sources represents a challenge for 5 
effective EAA systems and the results presented here demonstrate the inherent 6 
difficulties.  7 
 8 
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